|About Us||Patients, Families & Visitors||For Health Professionals||Careers||Research & Training||Ways to Give|
Dr. V.M. Venkatesan, MD, DLO(E), FRCS(E), FRCPC
Division of Radiation Oncology
Department of Oncology
University of Western Ontario
and Staff Radiation Oncologist
London Regional Cancer Program
London Health Sciences Centre
Radiation oncology with special interest in head and neck cancer and genitourinary cancers.
Residency in Otolaryngology, University Hospital of Wales, Cardiff, U.K.
Residency in Radiation Oncology, University of Western Ontario, London, Ontario
Fellowship in Radiation Oncology, University of Western Ontario, London, Ontario
Head and Neck Brachytherapy Training, Nancy, France
Perera F, Chisela F, Stitt L, Engel J, Venkatesan V. "TLD skin dose measurements and acute and late effects after lumpectomy and high-dose-rate brachytherapy only for early breast cancer." Int J Radiat Oncol Biol Phys. 2006 May 1; 65(1):309-10.
Hamilton S, Venkatesan V, Matthews TW, Lewis C, Assis L. "Computed tomographic volumetric analysis as a predictor of local control in laryngeal cancers treated with conventional radiotherapy." J Otolaryngol. 2004 Oct; 33(5):289-94.
Pollock A, DeSilvio M, Khor IY, Li R, Al Saleem T I, Hammond M.E. Venkatesan VM, Lawson CA, Roach M, Shipley WU, Hanks GE, Sandler HM. "KI-67 Staining is a Strong Predictor of Distant Metastases and Mortality for men with Prostate Cancer Treated with Radiotherapy plus Androgen suppression: RTOG Trial 92-02." J. Clin Oncol. 2004 June 1: 22(11): 2133-40.
Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horowitz EM, Lawton C, Rosenthal SA, Sandler HM, Shipley WU; Radiation Therapy Oncology Group.
"Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02." J Clin Oncol. 2004 Jan 15; 22(2):386.